Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.
By J. V. van Burik, V. Ratanatharathorn, D. Stepan, Carole B. Miller, J. Lipton, D. Vesole, N. Bunin, D. Wall, J. Hiemenz, Y. Satoi and 2 more. Clinical Infectious Diseases, 2004
702 citations recorded by the source corpus.
Subfields: Epidemiology, Infectious Diseases, Oncology
View Paper: https://www.semanticscholar.org/paper/dfd6f958634367558cb1b50e9900b59a597b70d5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
Citations in the corpus
- Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. (2008, neutral): “Although micafungin showed a trend towards a decreased incidence of Aspergillus infection (compared with fluconazole) in HSCT, there were small numbers of breakthrough infections in the patients studied, and the requirement for daily IV therapy further limited widespread use [287].”
- Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplant Recipients: A Global Perspective (2009, background): “One study has shown micafungin to be effective in preventing invasive fungal infections (including fever) when administered during neutropenia [425], but the incidence of invasive aspergillosis is low during the preengraftment phase, so antimold efficacy could only show a display of activity rather ”
- Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America (2009, background): “Micafungin has been shown to prevent fungal infections in hematopoietic stem cell transplant recipients [42, 128], but micafungin and anidulafungin have not been studied as empirical therapy for neutropenic patients.”